Left Ventricular Dysfunction - Pipeline Review, H1 2018

Date: January 18, 2018
Pages: 47
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: L3986B5FEECEN
Leaflet:

Download PDF Leaflet

Left Ventricular Dysfunction - Pipeline Review, H1 2018
Left Ventricular Dysfunction - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Left Ventricular Dysfunction - Pipeline Review, H1 2018, provides an overview of the Left Ventricular Dysfunction (Cardiovascular) pipeline landscape.

Left ventricular dysfunction is the most common cause of congestive heart failure. Symptoms include fluid retention, dizziness, fatigue, weakness, irregular heart beat and congested lungs. Risk factors include high blood pressure, diabetes, sleep apnea, alcoholism and coronary artery disease.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Left Ventricular Dysfunction - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Left Ventricular Dysfunction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Left Ventricular Dysfunction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Left Ventricular Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III and Phase II stages are 3 and 4 respectively.

Left Ventricular Dysfunction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Left Ventricular Dysfunction (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Left Ventricular Dysfunction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Left Ventricular Dysfunction (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Left Ventricular Dysfunction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Left Ventricular Dysfunction (Cardiovascular)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Left Ventricular Dysfunction (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Left Ventricular Dysfunction (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Global Markets Direct Report Coverage
Left Ventricular Dysfunction - Overview
Left Ventricular Dysfunction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Left Ventricular Dysfunction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Left Ventricular Dysfunction - Companies Involved in Therapeutics Development
Bayer AG
Innopharmax Inc
Mesoblast Ltd
Novartis AG
Quantum Genomics SA
TiGenix NV
Left Ventricular Dysfunction - Drug Profiles
(sacubitril + valsartan) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AlloCSC-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1142524 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
carvedilol phosphate CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MPC-150IM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QGC-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Left Ventricular Dysfunction - Dormant Projects
Left Ventricular Dysfunction - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Left Ventricular Dysfunction, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Left Ventricular Dysfunction - Pipeline by Bayer AG, H1 2018
Left Ventricular Dysfunction - Pipeline by Innopharmax Inc, H1 2018
Left Ventricular Dysfunction - Pipeline by Mesoblast Ltd, H1 2018
Left Ventricular Dysfunction - Pipeline by Novartis AG, H1 2018
Left Ventricular Dysfunction - Pipeline by Quantum Genomics SA, H1 2018
Left Ventricular Dysfunction - Pipeline by TiGenix NV, H1 2018
Left Ventricular Dysfunction - Dormant Projects, H1 2018
Left Ventricular Dysfunction - Discontinued Products, H1 2018

LIST OF FIGURES

Number of Products under Development for Left Ventricular Dysfunction, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Bayer AG
Innopharmax Inc
Mesoblast Ltd
Novartis AG
Quantum Genomics SA
TiGenix NV
Skip to top


Erectile Dysfunction - Pipeline Review, H1 2018 US$ 2,000.00 Jan, 2018 · 113 pages
Left Ventricular Dysfunction - Pipeline Review, H2 2017 US$ 2,000.00 Jul, 2017 · 61 pages

Ask Your Question

Left Ventricular Dysfunction - Pipeline Review, H1 2018
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: